Advair

Type: Product
Name: Advair
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Cipla down 2% on Nomura downgrade, valuations expensive

Shares of Cipla fell more than 2 percent intraday Wednesday after Nomura downgraded the stock to reduce from neutral rating, citing valuation to be expensive.The brokerage has price target on the stock at Rs 569, implying 9.7 percent potential downsi ... [Published Moneycontrol.com - 1 hour ago]
First reported Sep 15 2014 - Updated Sep 16 2014 - 1 reports

Sensex below 27,000; Hindalco, GAIL top losers

M arkets continue to trade weak in the morning trades weighed down by Index heavy weights HDFC, ITC, RIL and Infosys contributing nearly 100 points to the decline on the 30-share index.By 10.25 AM, the Sensex is lower by 203 points at 26,858 mark and ... [Published rediff.com - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Cipla hits new high; stock gains 10% in two days

Cipla has rallied 3% to Rs 631, also its record high on National Stock Exchange (NSE) in otherwise weak market.In past two trading sessions, shares of pharmaceutical company have rallied nearly 10% from Rs 575, compared to 1% decline in CNX Nifty.The ... [Published Business Standard India - Sep 15 2014]
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

Vectura Group Following A Familiar Path

Summary Vectura Group isn't well-known, but it has a broad and deep portfolio of patents and technology for the formulation, manufacture, and administration of respiratory drugs. Novartis's Ultibro and Seebri are selling well in the EU and Ultibro could ... [Published Seeking Alpha - Sep 13 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Cipla targets asthma market with Advair copy

Indian pharma company Cipla has begun selling a generic version of GlaxoSmithKline’s (GSK) combination asthma treatment Advair (fluticasone/salmeterol) in Germany and Sweden.The firm also has its sights set on the US, where GSK’s patent on the drug has ... [Published RSC - Sep 10 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Physician Views: Lessons from ERS on the LABA/LAMA and triple combination opportunities in COPD

With the opportunity for LABA/LAMA and LABA/LAMA/ICS combination therapies seen as critical in expanding the size of the COPD market, a number of presentations at this week's European Respiratory Society (ERS) congress will have been assessed with i ... [Published FirstWord Pharma - Sep 09 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 4 reports

Cipla launches generic version of Advair asthma drug in Germany, Sweden

Cipla has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair. “In Germany the new product is distributed under the name Serroflo, whereas in Sweden the combination is launched as Salmeterol/Fluticasone ... [Published Business Standard India - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 2 reports

Still sick, so now what?

I've struggled with major illnesses most of my life. I was initially diagnosed with fibromyalgia and asthma about 15 years ago. In 2009, I finally had to quit working full time and was diagnosed with polymyalgic rheumatica. I could not manage my symptoms ... [Published HealthBoards - Sep 03 2014]
First reported Sep 01 2014 - Updated Sep 02 2014 - 5 reports

Cipla's generic of GSK's Advair for asthma marks expansion into Europe

Indian generic drugmaker Cipla has entered the respiratory market in Germany and Sweden with its Serroflo (salmeterol/fluticasone MDI).Serroflo is the generic version of UK pharma major GlaxoSmithKline (LSE: GSK)’s Advair, and aside from Croatia where ... [Published Pharma Letter - Sep 02 2014]
First reported Sep 01 2014 - Updated Sep 02 2014 - 10 reports

Cipla hits record high

Cipla jumped 6.87% to Rs 566.10 at 10:47 IST on BSE on reports the company has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair.Meanwhile, the S&P BSE Sensex was up 87.09 points or 0.32% at ... [Published Capital Market - Sep 02 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

GSK welcomes US OK for Arnuity in light of declining Advair sales

US FDA approval of the inhaled corticosteroid (ICS) asthma drug Arnuity will help offset declining sales of the off-patent bestseller Advair, says GlaxoSmithKline.Advair – a combination of fluticasone propionate and salmeterol xinafoate - has continued ... [Published In-Pharmatechnologist - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Advair, Symbicort charge Americans 5x what they charge Europeans

International pharmaceutical giants GlaxoSmithKline and AstraZeneca are charging Americans approximately five times what they charge the French for the popular asthma medicines Advair (Seretide in France) and Symbicort. Advair 500 goes for $73 (55 euros) ... [Published AMERICAblog News| A great nation deserves the t ... - Aug 21 2014]

Quotes

According to the report, the valuation looks expensive as the brokerage sees limited upside risk to earnings in the near term. "Cipla’s stock has increased 64 percent since May 31 2014 versus the Sensex return of 11 percent. The stock trades at 35.7x FY15F and 26x FY16F EPS of Rs 17.65 and Rs 24.27 respectively, a 30-45 percent premium to peers" it elaborated
... AMA President-elect Steve J Stack said, "The current generation of EMRs and the way they are deployed is not supporting the quality of care we need it to." As Meaningful Use requirements continue to spur uptake of EMR systems, many doctors have had difficulty keeping up—saying the systems take up too much...
"It's been like a roller coaster ride," he said. "As I parent I wouldn't want my child to have to take any medicine, but you have to deal with the cards you've been dealt, and it's worked out."
"This finding would suggest that most patients in this clinical trial might have had improvement in symptoms without mepolizumab simply by the institution of good clinical practice" he wrote

More Content

All (149) | News (118) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Cipla down 2% on Nomura downgrade, valuations e... [Published Moneycontrol.com - 1 hour ago]
Six things for pharma marketers to know: Tues... [Published Medical Marketing And Media - 16 hours ago]
Sensex below 27,000; Hindalco, GAIL top losers [Published rediff.com - Sep 15 2014]
Cipla hits new high; stock gains 10% in two days [Published Business Standard India - Sep 15 2014]
Vectura Group Following A Familiar Path [Published Seeking Alpha - Sep 13 2014]
Company Update (NASDAQ:ESRX): Express Scripts E... [Published Tamar Securities - Sep 12 2014]
Cipla targets asthma market with Advair copy [Published RSC - Sep 10 2014]
Equity Research Report 10 Sep 2014 By Ways2Capital [Published Prlog - Sep 10 2014]
Management of Corruption Risks – Business Lesso... [Published FCPA Compliance and Ethics Blog - Sep 10 2014]
Physician Views: Lessons from ERS on the LABA/L... [Published FirstWord Pharma - Sep 09 2014]
Teva Pharmaceuticals New Drug Aims to Reduce As... [Published Motley Fool Discussion Boards - Sep 09 2014]
Exercise-Induced Asthma: Manageable Condition S... [Published Winter Haven News Chief - Sep 09 2014]
UPDATE 1-Cost a focus as GSK takes lead in new ... [Published London South East - Sep 08 2014]
HDFC Sec upgrades Cipla to Buy with target of R... [Published MyIris - Sep 08 2014]
GSK, Pfizer partnership wins EU nod for HIV pil... [Published FiercePharma - Sep 05 2014]
What's New in Asthma Management? [Published Yahoo! News - Sep 05 2014]
What’s New in Asthma Management? [Published US News & World Report - Sep 04 2014]
Squalls and choppy waters at drug firm don't fa... [Published Irish Independent - Sep 04 2014]
Cipla Europe launches may trigger rerating [Published Economic Times - Sep 03 2014]
Indian stock market daily morning report (Septe... [Published Stock Markets Review - Sep 03 2014]
Cipla launches generic version of Advair asthma... [Published Business Standard India - Sep 03 2014]
CIPLA : Launches copy of gsk's asthma drug in g... [Published 4 Traders - Sep 03 2014]
Indian stock market and companies daily report ... [Published Stock Markets Review - Sep 03 2014]
Top 10 Nifty stocks that surged upto 42% since ... [Published Economic Times - Sep 03 2014]
Still sick, so now what? [Published HealthBoards - Sep 03 2014]
Five things for pharma marketers to know: Tuesd... [Published Medical Marketing And Media - Sep 02 2014]
Cipla's Advair copy gathers steam with rollouts... [Published FiercePharma - Sep 02 2014]
GSK investors call for chairman's head after so... [Published FiercePharma - Sep 02 2014]
Still ill, so now what? [Published HealthBoards - Sep 02 2014]
Nifty, Sensex to keep pushing higher – Tuesday ... [Published Money Life - Sep 02 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Management of Corruption Risks – Business Lesso... [Published FCPA Compliance and Ethics Blog - Sep 10 2014]
The Department of Justice (DOJ) and Securities and Exchange Commission (SEC) have made it abundantly clear over the past several years that companies should assess their risk and then manage their own risks. In the anti-corruption space, simply putting ...
Still sick, so now what? [Published HealthBoards - Sep 03 2014]
I've struggled with major illnesses most of my life. I was initially diagnosed with fibromyalgia and asthma about 15 years ago. In 2009, I finally had to quit working full time and was diagnosed with polymyalgic rheumatica. I could not manage my symptoms ...
Still ill, so now what? [Published HealthBoards - Sep 02 2014]
I've struggled with major illnesses most of my life. I was initially diagnosed with fibromyalgia and asthma about 15 years ago. In 2009, I finally had to quit working full time and was diagnosed with polymyalgic rheumatica. I could not manage my symptoms ...
Advair, Symbicort charge Americans 5x what they... [Published AMERICAblog News| A great nation deserves the t ... - Aug 21 2014]
International pharmaceutical giants GlaxoSmithKline and AstraZeneca are charging Americans approximately five times what they charge the French for the popular asthma medicines Advair (Seretide in France) and Symbicort. Advair 500 goes for $73 (55 euros) ...
How health insurance companies still cheat cust... [Published AMERICAblog News - Aug 20 2014]
One of the things that the Affordable Care Act (aka ACA, aka Obamacare) was meant to do was make sure that people with pre-existing medical problems could get health insurance. And that their insurance was  affordable.  But that may not be the case ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.